Precision therapy in acromegaly caused by pituitary tumors: How close is it to reality?

Cheol Ryong Ku, Vladimir Melnikov, Zhaoyun Zhang, Eun Jig Lee

Research output: Contribution to journalReview articlepeer-review

4 Citations (Scopus)


Acromegaly presents with an enigmatic range of symptoms and comorbidities caused by chronic and progressive growth hormone elevations, commonly due to endocrinologic hypersecretion from a pituitary gland tumor. Comprehensive national acromegaly databases have been appearing over the years, allowing for international comparisons of data, although still presenting varying prevalence and incidence rates. Lack of large-scale analysis in geographical and ethnic differences in clinical presentation and management requires further research. Assessment of current and novel predictors of responsiveness to distinct therapy can lead to multilevel categorization of patients, allowing integration into new clinical guidelines and reduction of increased morbidity and mortality associated with acromegaly. This review compares current data from epidemiological studies and assesses the present-day application of prognostic factors in medical practice, the reality of precision therapy, as well as its future prospects in acromegaly, with a special focus on its relevance to the South Korean population.

Original languageEnglish
Pages (from-to)206-216
Number of pages11
JournalEndocrinology and Metabolism
Issue number2
Publication statusPublished - 2020

Bibliographical note

Publisher Copyright:
© 2020 Korean Endocrine Society

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'Precision therapy in acromegaly caused by pituitary tumors: How close is it to reality?'. Together they form a unique fingerprint.

Cite this